10x Genomics (TXG) Asset Writedowns and Impairment (2023 - 2025)

10x Genomics (TXG) has 3 years of Asset Writedowns and Impairment data on file, last reported at $114000.0 in Q1 2025.

• For the quarter ending Q1 2025, Asset Writedowns and Impairment fell 95.35% year-over-year to $114000.0; the trailing twelve-month figure through Mar 2026 stood at $114000.0 (down 84.03% YoY), and the FY2025 full-year result was $814000.0, down 73.35% from the prior year.
• Asset Writedowns and Impairment fell to $114000.0 in Q1 2025, from $600000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $7.1 million in Q4 2023 to a low of $114000.0 in Q1 2025.
• A 3-year average of $2.6 million and a median of $2.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment tumbled 91.5% in 2024 and plunged 95.35% in 2025, its largest moves.
• Tracing TXG's Asset Writedowns and Impairment over 3 years: stood at $7.1 million in 2023, then plunged by 91.5% to $600000.0 in 2024, then tumbled by 81.0% to $114000.0 in 2025.
• Business Quant data shows TXG's Asset Writedowns and Impairment at $114000.0 in Q1 2025, $600000.0 in Q4 2024, and $2.5 million in Q1 2024.